MX2022016342A - Union de anticuerpos multiespecificos a bcma. - Google Patents

Union de anticuerpos multiespecificos a bcma.

Info

Publication number
MX2022016342A
MX2022016342A MX2022016342A MX2022016342A MX2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A
Authority
MX
Mexico
Prior art keywords
bcma
specific antibodies
antibodies binding
antibodies
sup
Prior art date
Application number
MX2022016342A
Other languages
English (en)
Inventor
Ute Schellenberger
Nathan Trinklein
Katherine Harris
Omid Vafa
Aldred Shelley Force
Harbani Malik
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2022016342A publication Critical patent/MX2022016342A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Se dan a conocer anticuerpos multiespecíficos de cadena pesada humana (por ejemplo, UniAbsTM) que se unen a BCMA, junto con métodos para preparar tales anticuerpos, composiciones, incluyendo composiciones farmacéuticas, que comprenden tales anticuerpos y su uso para tratar trastornos que se caracterizan por la expresión de BCMA.
MX2022016342A 2020-06-30 2021-06-30 Union de anticuerpos multiespecificos a bcma. MX2022016342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046477P 2020-06-30 2020-06-30
PCT/US2021/039961 WO2022006316A1 (en) 2020-06-30 2021-06-30 Multi-specific antibodies binding to bcma

Publications (1)

Publication Number Publication Date
MX2022016342A true MX2022016342A (es) 2023-01-24

Family

ID=77127069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016342A MX2022016342A (es) 2020-06-30 2021-06-30 Union de anticuerpos multiespecificos a bcma.

Country Status (16)

Country Link
US (1) US20230257473A1 (es)
EP (1) EP4171750A1 (es)
JP (2) JP2023532129A (es)
KR (1) KR20230038211A (es)
CN (1) CN116472049A (es)
AU (1) AU2021300179A1 (es)
BR (1) BR112022027101A2 (es)
CA (1) CA3189297A1 (es)
CL (1) CL2022003754A1 (es)
CO (1) CO2023000808A2 (es)
CR (2) CR20250505A (es)
IL (1) IL299027A (es)
JO (1) JOP20220357A1 (es)
MX (1) MX2022016342A (es)
PE (1) PE20230464A1 (es)
WO (1) WO2022006316A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2762835C2 (ru) 2016-08-24 2021-12-23 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
WO2024117786A1 (ko) 2022-12-02 2024-06-06 주식회사 엘지에너지솔루션 배터리 팩 및 그의 제조 방법
AU2024295287A1 (en) * 2023-07-13 2025-10-16 Telix Pharmaceuticals (Innovations) Pty Ltd Humanised antibodies and uses thereof
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
DE102010039018B4 (de) * 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2017031104A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
RU2762835C2 (ru) 2016-08-24 2021-12-23 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
JP7755371B2 (ja) * 2017-06-09 2025-10-16 アヴェンセル ユーロップ ゲー・エム・ベー・ハー 共通キメラ抗原受容体発現免疫細胞のためのターゲティングモジュールならびに癌、感染および自己免疫障害の処置における使用
IL312322B2 (en) * 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
WO2018237006A1 (en) * 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
KR102757010B1 (ko) 2017-06-30 2025-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 인간 도메인을 갖는 항-b 세포 성숙화 항원 키메라성 항원 수용체
EP3581200A1 (en) * 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders

Also Published As

Publication number Publication date
CN116472049A (zh) 2023-07-21
WO2022006316A1 (en) 2022-01-06
EP4171750A1 (en) 2023-05-03
JP2026071208A (ja) 2026-04-28
BR112022027101A2 (pt) 2023-03-14
CO2023000808A2 (es) 2023-02-16
IL299027A (en) 2023-02-01
AU2021300179A1 (en) 2023-02-02
CA3189297A1 (en) 2022-01-06
JOP20220357A1 (ar) 2022-12-29
JP2023532129A (ja) 2023-07-26
CL2022003754A1 (es) 2023-07-07
CR20250505A (es) 2026-01-13
CR20220656A (es) 2023-03-01
PE20230464A1 (es) 2023-03-14
KR20230038211A (ko) 2023-03-17
US20230257473A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
PH12021552538A1 (en) Heavy chain antibodies binding to psma
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
ZA201903985B (en) Anti-bcma heavy chain-only antibodies
MX2022013453A (es) Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
CR20200322A (es) Anticuerpos de cadena pesada que se unen a cd22
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12023552763A1 (en) Agonistic anti-il-2r antibodies and methods of use
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MX2022007140A (es) Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3).
MX386086B (es) Composicion de cannabis
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
NZ737399A (en) Ccr2 modulators
MX2022000712A (es) Moduladores de nlrp3.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use